Bladder Cancer - Results from #520

REVIEW UroToday

Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer. March 15, 2024

The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. March 14, 2024

Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection. March 14, 2024

Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro. March 14, 2024

Impact of Age >70 Years on Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin March 13, 2024

The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer. March 13, 2024

Cost-Utility of Initial Management of High-grade T1 Bladder Cancer with Intravesical BCG vs Immediate Radical Cystectomy. March 13, 2024

Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma. March 12, 2024

The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study. March 12, 2024

FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. March 12, 2024

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. March 11, 2024

Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience. March 11, 2024

Real-world evidence of tumor and patient characteristics and survival with avelumab maintenance after chemotherapy for advanced and metastatic urothelial carcinoma. March 8, 2024

Prospective evaluation of sexual health following radical cystectomy due to bladder cancer. March 8, 2024

Impact of Agent Orange Exposure on Non-muscle Invasive Bladder Cancer Outcomes. March 8, 2024

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer March 7, 2024

Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations. March 7, 2024

A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity. March 7, 2024

Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy. March 7, 2024

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma March 6, 2024

Page 27 of 517